🎁 Black Friday: up to 50% off of annual plans
Strata Critical Medical, Inc. (SRTA)
NASDAQ: SRTA · Real-Time Price · USD
4.560
-0.270 (-5.59%)
At close: Nov 20, 2026, 4:00 PM EST
4.749
+0.189 (4.15%)
After-hours: Nov 20, 2026, 7:30 PM EST
← View all transcripts

UBS Global Healthcare Conference

Nov 10, 2026

Summary

The strategy is shifting toward an integrated transplant-services network, with local recovery, NRP and acquisitions supporting growth and customer cost efficiency. Management achieved its 13% medium-term organic margin target in the latest quarter and expects FY2026 free-cash-flow conversion of 60%, rising toward the target range’s high end.

Patrick Wood
Head of US MedTech Research, UBS

Picks the songs. That's the key. Who picks the playlist? Welcome, everyone. It's Patrick Wood on the UBS MedTech team. It's a delight to have Melissa, Will, and Matt here today, who collectively are the dream team at Strata. Thanks very much for coming, guys. Really appreciate the time. I think, maybe to level set people, probably 18 months, two years ago, people kind of knew you as Blade. You're in a different spot. Today, you're in a very different form of business, fast growth area. Maybe just to make sure everyone's on the same page, walk people through that journey to what you are today. I'll throw it open to any of you. Fight over who has to answer.

Will Heyburn
Co-CEO and CFO, Strata

For several years, the fastest growing part of our business was our healthcare segment, focused on transplant, where, for folks who aren't familiar, there is a huge problem in America, which is there are not enough donor organs, and there is extremely high demand for people who, if they don't get these donor organs, they're unfortunately not going to be able to survive. The way that we've been able to help solve this problem with the people that we partner with at transplant centers and organ procurement organizations and with medical device companies is to do what we can to increase the supply of donor organs that can be utilized.

It's led to significant growth in the number of transplants that happen in America, and it's also led to pretty dramatic growth, averaging about 15% per year, in the number of donation after circulatory death transplants that happen in the United States. It's a whole new category of organ donor that's been enabled by technology, by new regulation, and Strata has tried to put all the pieces together in a single integrated offering to partner with transplant centers, which are the hospitals that have the patient that's going to receive the transplant, partner with OPOs, which are the groups that help identify donors, to come up with the most efficient, cost-effective way to be able to successfully recover organs from those donors and get them very quickly, because you have very limited time, to the recipients for whom it will be a life-saving procedure.

As we saw the opportunity, the need, we decided about a year ago, to your point, to divest the passenger part of our business, focus entirely on this, and then add clinical capabilities to create that full end-to-end offering. So now, not only are we providing the logistics, we're providing surgeons that can recover organs. We're providing perfusion, so we provide normothermic regional perfusion, where machines are able to repair the damage that's done in the dying process to those organs. It's a very cost-effective way to enable you to use an organ from a donor whose heart has stopped. Then we also are able to partner with device companies to either transport or operate other kinds of machines that can do very similar things.

We think we have created really what we call an open source infrastructure layer for the transplant community, and importantly, we build that clinical part of our business on the very sturdy foundation of a company that provides services in terms of perfusion for regular way cardiac surgeries to hundreds of hospitals across the U.S. It happens to be the same kind of people, perfusionists, and the same equipment that you use in those situations that we can also use in our transplant scenarios. We get some economies of scale, and we're growing incredibly quickly, both organically and through acquisition, because all this change in transplant, which has been for the better, which has resulted in a lot of growth, has meant that some of the old ways of doing things, which were very regionalized, are no longer the standard practice.

That has meant that a lot of the smaller providers of services like ours, because they don't have the national scale, they're no longer able to meet all their customers' needs. That's resulted in us taking some share. It's also resulted in us partnering with a lot of those companies through acquisition, bringing them into our platform, bringing great people, great clinicians into the Strata business, and then making everything run more efficiently, both for those individuals that now can spend more time in operating rooms and less time on airplanes, and for our customers. We're thrilled with the transition we've made. We're thrilled with the opportunity we have to help, in our way, solve this really important life-saving problem that everyone's facing in America. We have so many different ways to achieve that objective, both organically and through acquisition.

Couldn't be more excited about the decisions that we've made strategically and the opportunities that we have ahead.

Patrick Wood
Head of US MedTech Research, UBS

Definitely want to dig into all of those. Melissa, you had a background in aviation before. Obviously, healthcare has its own distinctions versus passenger, with some very obvious differences between the two. Were there things that surprised you on the healthcare aviation side that you weren't expecting around challenges or unique ways of having to run that business versus the other side?

Melissa Tomkiel
Co-CEO and General Counsel, Strata

Well, the biggest difference is the 24-hour nature of the healthcare business. It takes the right operators, the right mentality amongst pilots and mechanics to really staff up an organization that's accessible 24/7. The best thing going for us here is that we're mission-driven, right? Everyone knows that all of those flights result in saving lives. That's probably the biggest distinction. The other one being, with organ donation, with DCDs, unfortunately about a quarter of the time, it's what we call a dry run, meaning the donor didn't decease quickly enough, the organs are unusable, and the recovery surgeon goes home empty-handed. That doesn't happen in normal aviation, but what it allows for, what it presents itself for is the ability to provide the most cost-efficient way to handle those situations for our transplant center customers.

The way to do that is to have the national scale with our 20 or so aviation hubs that are strategically around the country, so that when we have a plane in place where a donor is, if it's a dry run, we haven't fired up an engine. It's minimal cost to our customer, as opposed to having to fly out from the transplant center, fly a team in, fly back empty-handed. Now you've just burned the transplant center's surgeon's time. You've burned a lot of their money because they're paying for a private jet to fly somewhere and back with no organ. Building the national infrastructure with aviation hubs coupled with local surgeons who are available to, we call it self-report, to drive or fly commercially to the donor OR is the key differentiator here.

This is where we are set apart from the very good, but the very local operators that we are either competing with or working with, or some of whom have been acquisition targets. That's really the biggest difference in how you think about optimizing for cost efficiency and time efficiency, because every minute matters when you're transporting a heart that's outside of a body. The more assets you have in the more strategic locations is going to give you that advantage.

Patrick Wood
Head of US MedTech Research, UBS

To that network effect, and both of you in your answers talked about M&A, naturally. Matt and all of you, how do you think about the M&A capacity here, the ability to get that network effect, to get larger? How do you think about capital allocation from an M&A perspective?

Will Heyburn
Co-CEO and CFO, Strata

Want to take that, Matt?

Matt Schneider
CFO of Clinical Services and VP of Finance and Investor Relations, Strata

There's a significant opportunity to strengthen exactly what Melissa just said. We have this integrated platform, local delivery network that we're building, and entering additional geographic areas across the country would strengthen that because the more time we can deliver our services when we're closer to the donor hospital, the more cost efficiencies we could deliver to the customer. We're building out the platform to try to be in more areas to diversify our customer exposure and to be able to deliver that operational cost savings more of the time. That's across both our NRP perfusion, our surgical recovery network and services, our CT or cardiothoracic perfusion services, and really across logistics. The more places we are across the country closer to the customer, the better we're able to deliver that savings to the customer.

That's what we're really focused on, strengthening the value proposition to the customer. There's also just the financial rationale behind it of how we're going to market, the acquisitions we're doing, the multiples that we're acquiring the companies at, and we're really excited about deploying capital going forward from here.

Patrick Wood
Head of US MedTech Research, UBS

If I think about the space overall, and when you're speaking to your customers, because you have a lot of different customers with a lot of different challenges, what's the number one pinch point that you guys are running into when it comes to surgeons being like, "Help, this is what I need help with"? Is it lower quality DCD organs that aren't getting there or they're not being warned ahead of time? Is it a modality question, NMP, NRP, or whatever? What's the number one bit of feedback that your customers are saying, "This is what we need the most help with"?

Will Heyburn
Co-CEO and CFO, Strata

I think they want us to be flexible and nimble, and that's something that is really a core value of ours. Believe that the customer is always right, particularly when they're a transplant surgeon. We accommodate whatever medical device they want to utilize. We accommodate the timing, and most importantly, they're looking for flexibility around being able to attempt a recovery in a situation where there's some significant probability that the organs are not going to be able to be used and do that, as Melissa said, we set it up in such a way that hopefully we never had to turn on an airplane before we get to that point in time. That, I think, is a huge unlock because, as we like to say, it transforms a, "Okay, I'm going to pass on this," to a 50% chance of saving multiple lives.

That's, at the end of the day, what our customers are focused on, but they have limited resources, limited capacity, and you can't fly airplanes all across the country if you assess a 40% or 50% chance that the organs are not going to be usable. We're trying as much as possible to make that possible.

Patrick Wood
Head of US MedTech Research, UBS

Melissa, Q3, I think clinical services was just growing immensely and doing really well. Maybe if you could paint the background for people on what you're seeing there, how that growth has been happening.

Melissa Tomkiel
Co-CEO and General Counsel, Strata

Sure. Well, so kind of looking at it from a 30,000-foot view, DCD donors is growing as a percentage of all donations. NRP is growing in the percentage of use and adoption in DCD donation. This is making things a little more complicated, right? It's more time-consuming to do these recoveries. A lot of them are using NRP. The vast majority now are using NRP, and it has become the emergent need of our transplant center customers to use a third party for that recovery service. We've touched on some of the reasons why, right? It takes more time, there's a risk of a dry run, and it requires perfusion. So, that's why. We saw that need growing, and we were really happy that we could be nimble and flexible, to Will's point, and cost-efficient in deploying our local recovery model.

We completed an acquisition of another recovery company that bolted onto our platform that gave us really strategic positioning of recovery surgeons in Florida and California. We have a lot of volumes there. That was a big catalyst as well, combined with our organic growth in recovery and with NRP. That is kind of where we see the puck has gone. We kind of got ahead of it, which was great, but there is still going to be a lot of more growth there, for sure.

Patrick Wood
Head of US MedTech Research, UBS

NRP, and correct me if any of these, from your perspective, are different, but typically more of a multi-organ recovery situation. You are perfusing a lot of organs simultaneously. They all begin at different spots. I would imagine it is logistically more challenging, because you are taking multiple organs and taking them all sorts of different directions. Does not that lend itself more to one larger logistics provider who is able to handle each of those distinct donations concretely as one point of contact, rather than trying to piece together a selection of different providers for each of the organs? Or am I stretching here?

Will Heyburn
Co-CEO and CFO, Strata

No, I think our go-to-market there is really unique in the industry in that it is built on a foundation of contractual retainer relationships with organ procurement organizations. We are contracted then to provide all the NRP that might be needed in the geography, the donor service area that that OPO is responsible for. Then any areas nearby, if we have a transplant center that maybe needs to do NRP on a donor that is just outside of that area and it is not offered by the OPO, we can use those same staff and resources to be able to provide that service much more efficiently. In many cases, we are also providing surgical recovery through that retainer contract with the OPO.

That completely changes the mindset of a transplant center, because now the way that they are paying for both of those services, the recovery and the NRP, is just coming through what they call the standard acquisition cost that the OPO is charging them. If you go back to the example of, "I do not want to risk it on this one. I do not want to travel," now all the services through an OPO contract with us are already taken care of locally, and you can go make that attempt. To your other point, you do see about 50% more usable organs from donors that go through the NRP process, because it benefits all of the potential donating organs rather than devices have a really important role to play in the ecosystem, but definitionally, you are just putting one organ in that device.

It is almost like a public good, and we believe very strongly that the vast majority, if not all, DCD donors should go through the NRP process because of the public good benefit of seeing more usable organs that come out of that. The most efficient way to do that is to do it locally, and that is why we really built the foundation of our business with that as the anchor point.

Patrick Wood
Head of US MedTech Research, UBS

I am trying to think of how to ask this question that does not give you guys a headache. Maybe general counsel is going to be a good spot to answer. There has been a lot of noise with the OPOs, right? There was the anxiety around decertification, and then backtracking a little bit on that, and then some vertical integration discussion, potentiality. Not clear if that is actually happening. How do you think the OPOs are generally set up at the moment as partners for you guys, and do you think that structure is likely to change in any meaningful way over the next five years or so?

Melissa Tomkiel
Co-CEO and General Counsel, Strata

CMS was pretty blatant about a path toward decertification. I think we can all operate under the assumption that there will be consolidation and there will be fewer OPOs in the future. We view this as a positive for the industry, right? We want accountability, we want high standards, and we want OPOs to pursue more organs. That is the biggest need, as Will talked about in the beginning. People are still dying. 15,000 people or so are still dying every single day waiting for an organ. It is a good thing for us, and it is a good thing that OPOs are now looking to do more NRP, right, to yield more organs. That is exactly where we can come in and help them. If they have capacity issues for recoveries, that is where we have our retainer agreements with them. Same thing with NRP.

For us, we view this overall as a positive. We have seen already with the decertification and then with some voluntary consolidation, us just getting further entrenched with the OPOs.

Patrick Wood
Head of US MedTech Research, UBS

Makes sense. The one I find is interesting that almost never comes up with discussions with investors is those early supply side of things, the number of people actually signing up for organ donation and that side of things. I think it was earlier this year, there was a little bit of a drop, and then, because there was some New York Times articles and things like that. Yet we've got an administration where a key goal of this administration is to increase the amount of transplants that are happening. That's very clearly a stated goal. What do you think can or can't be done to try and get that very, very top of the funnel a little bit more engaged? I can't imagine the U.S. would ever move to a system of automatic enrollment. That seems very unlikely. Is there anything we can do?

Is it just an education thing? I know it's a very broad question.

Will Heyburn
Co-CEO and CFO, Strata

It's about rebuilding trust, and there's been a lot of new rulemaking, some of it very technical in nature, some of it more easily understood. It's just trying to create consistency across the country around the way that this process is going to play out, and respect for the donor families that, on the worst day of their life, make this decision to potentially save two, three, four, five others. You're trying to learn about how this company works from an investor perspective. Imagine trying to learn all that when you're having the worst day of your life. It's a very, very difficult thing to explain, and the work that OPOs do is incredibly important.

I think the new rules that are creating more consistency around exactly the sequencing of how that happens and the process that you need to go through is going to help to rebuild that trust. That's the most important thing, and I think you've already seen it in the data in terms of the number of transplants that are occurring in the U.S. since that drop-off with some of the negative attention around things that could be made better and have been made better from a regulatory perspective.

Patrick Wood
Head of US MedTech Research, UBS

You guys obviously see the end-to-end of the whole process, as well as all the different technologies that are involved in that process. What can we do to get to a point where we shrink waiting lists even further? Is there a technological advance? Is it better logistics that help ensure that you get fewer failed implants and things like that, a lower discard rate? Because you see the entire chain. How much is there to be done to either increase the amount of DCD organs or reduce the discard rate, something like that?

Will Heyburn
Co-CEO and CFO, Strata

All of the above, but as you are hearing from us today, we think maybe the most important thing is the ability to attempt a recovery without having to spend so much money flying staff and equipment from all sorts of different locations around the country. That is why we feel, and you probably feel from us, a sense of urgency to continue building the scale to be able to accomplish that in more places. The regulatory tailwinds are with us as OPOs become more sophisticated, and many of them, as we talked about, are voluntarily banding together to be able to offer more of these services directly locally, in many cases through contracts with us or someone like us.

That is going to make the process for a transplant center simpler, and it is going to allow us to get more utilization out of the resources that already exist in the transplant community. As a real-life example, we acquired a business that had some surgeons in primarily Florida, as Melissa talked about, that were working for hospitals in Florida. What were they doing when those hospitals needed to recover an organ from across the country? They were flying.

When you then put that business and plug it into our platform, those surgeons are now not spending nearly as much time on airplanes and spending much more time in operating rooms. You are getting more recoveries out of the same number of surgeons as part of our platform. You are also able to pay those surgeons more because they are being more productive. They are getting more experience, which makes people trust them more.

They become more valuable to all of our customers because we are using them where they live, they are going to be happier, and we are using our other surgeons when we are recovering in those areas. The more progress we can make on this front, we think the better, and technology has a really important. We have had several new devices come to market in the U.S. We expect more next year. All of that is going to give transplant centers more options, more flexibility, maybe lower-cost ways to accomplish their mission.

Patrick Wood
Head of US MedTech Research, UBS

Definitely want to dig into that in a second. Matt, you guys are EBITDA positive now, producing free cash flow. How are you viewing the long-term margin and cash generation of the business? There's a scale benefit naturally, but also I'm sure there's things around scale effects and aircraft maintenance schedules and all that good stuff that can be done. If you were in our shoes, how would you think about the long-term trajectory of the business there?

Matt Schneider
CFO of Clinical Services and VP of Finance and Investor Relations, Strata

Starting with margins, we put out a medium-term target last year at our Investor Day. That was on an organic basis of a 13% margin, which we achieved in the latest quarter because of all the clinical acquisitions that we've done. It just kind of illustrates the opportunity over time, really as we mix the business towards clinical. The clinical profitability, the margin is inherently higher in most cases than our logistics business. Really, when you peel back the onion, there's been a really important mix shift improving the quality of the business, really from a margin, growth, and free cash flow conversion perspective that we'll talk about. The opportunity is to continue really to mix towards our clinical or transplant clinical revenue stream over time that should accrete to the gross margin level.

On SG&A, there's been great operating leverage we've seen there year to date. Our SG&A has been about flat for the last four quarters as we scaled up revenue, so you've seen a lot of operating leverage there. We'll see growth in SG&A going forward, but more like inflationary-type growth for the majority of that base. I think there's a strong outlook for operating leverage going forward and margin expansion from free cash flow conversion that we're really starting to see the cash generation come through, since we announced all these acquisitions over the last strategic transactions over the last year. There was a lot of deal-related cash costs initially, some working capital timing issues in the first half of the year, just normal timing, and you're really starting to see that with strong free cash flow conversion in the third quarter.

As we go forward, we're really excited about that continuing. Our CapEx overall, we should see great operating leverage on that. As we grow EBITDA, the free cash flow conversion should improve from here. We guided to a 60%-70% range at our Investor Day last year. We're going to do about 60% in 2026, and that should go higher towards the high end of the range moving forward.

Patrick Wood
Head of US MedTech Research, UBS

You mentioned obviously the clinical specialists. How are you able to find them? I'd imagine it's a competitive hiring process, finding all the right people. How are you finding them? How have you seen wage inflationary pressures in that market? Because the transplant market in general, and not all specialists, and it's quite an incestuous industry. Are you guys able to find the people you need, and is wage inflation in the right zone, or is it running hot?

Will Heyburn
Co-CEO and CFO, Strata

It's about having work for them to do. Melissa, you want to talk about some of the new business lines that are creating even more work?

Melissa Tomkiel
Co-CEO and General Counsel, Strata

Will had mentioned with our local recovery model, our surgeons are spending more time in the OR and less time on planes, which is good because that's part of their compensation structure. That's good for them, that's good for us, that's good for the recipients of those organs. It really is about keeping them captive and busy and well-paid. We had a customer, a hospital system customer that had an immediate need for support with cardiothoracic surgeries, not transplant-related. This is just open heart surgeries. They needed some backup support. In our spirit of always wanting to say yes to the customer, we utilized some of our recovery surgeons to provide the support and realized this is a great way to keep them busy, keep them paid, keep them happy, and with us.

That contract led immediately to another service line provided of physician assistants to the same healthcare system, which again, we're using some of our clinicians and perfusionists to provide that support. It's really about keeping them in the family, so to speak. I will say that we have a lot of buy-in. Our people and our team, and I think our ability to attract top talent, which I believe we have and will continue to attract, comes from the belief in what we're building and appreciating that we're doing it on scale, knowing at scale, knowing we can out-compete, but also that this is just going to keep growing. That has been a key component in our retention and recruitment.

Patrick Wood
Head of US MedTech Research, UBS

Interesting as an unexpected revenue line to suddenly run into. That is awesome. If I am thinking, Will, I think you mentioned about new technologies coming down the pike. I think many of us know some of those. How do you think that affects you guys? Gives you more options. I would imagine for some of them, maybe there is more flexibility around the timing of logistics because an organ can be kept in situ a little bit better. Maybe I am wrong about that. Less like which technology is going to win, more like what does this mean for you and Strata?

Will Heyburn
Co-CEO and CFO, Strata

We want to be a force multiplier for all of these medical device companies. We want to make it easier for them to get their product in the hands of the customer when they want to use them, and we want to provide skilled, talented hands that can do the cannulation, that can operate the device, that can perform maintenance, and we want to leverage our hubs to be able to store the devices so you do not need to fly them all across the country, and you can save our mutual customers money.

That has been our approach, is to support anything our customers want. We stock most of the devices that are out there today that are frequently used in transplant, and we make it very easy for our customer to ask us to take one off the shelf, and that is what we want to continue to do.

We do not get into arguments with our customers about what makes sense in a particular circumstance. Our job is to make it as efficient as possible to deploy whatever solution they think makes sense for a particular donor and a particular recipient, and that is where, again, our flexibility, our agility, that could be driving a little bit longer for a case that is nearby, that could be stretching the distance of how far we can fly. We just did recently a trip from Alaska to the Northeast.

Not a distance we usually travel, but we are there, and our business is set up, whether it is the diverse fleet we have through our asset-light model and only owning a very small number of airplanes, or the distributed network of clinicians and the distributed network of devices, we are set up to be able to say yes to many more scenarios than you could if you were captive to a very particular type of airplane or a very particular geography or a very particular device, et cetera.

Patrick Wood
Head of US MedTech Research, UBS

You're a network effect rather than a. And also the leases relative to the ownership, which don't want to tie yourselves down. I totally get that. I mean, three of you have done and had investor meetings. You've got your own calls. You do all this stuff. You hear all the questions. I'm curious for each of you. What kind of stuff comes up a lot externally that doesn't come up much internally, or vice versa? What do you spend a lot of time talking about internally that doesn't get a lot of airtime externally? Another way to phrase it would be, do you ever feel like there's the source of discussion, there's a bit of a disconnect between what people are focused on and where you think actually the industry is going or what your business represents? That's very open-ended.

I don't know who to throw into it first, just to

Melissa Tomkiel
Co-CEO and General Counsel, Strata

One person's view, I think we're pretty aligned.

Patrick Wood
Head of US MedTech Research, UBS

Yeah.

Melissa Tomkiel
Co-CEO and General Counsel, Strata

A lot of the hot topic is our growth, and a lot of that is M&A. We have a lot of capital to deploy. And we have another earnout payment coming. We have an undrawn revolver. There's a lot of wood to chop here, and there's a lot of excitement about what we're going to do with that and how we're going to execute on our growth plan.

Will Heyburn
Co-CEO and CFO, Strata

We obviously spend a lot of time internally talking about things that we don't release stats on publicly, but why were we not on time to pick someone up once last month? It should be 100%. What happened? How do we make sure that never happens again? Why did it take 30 minutes to recover from a mechanical issue? Why didn't we have a solution that could happen more quickly? We spend a lot of our time trying to get things to be absolutely perfect. Aviation is never perfect, and people are never perfect, so the way you do that is to have redundancy. That's what we're focused on a lot, just the customer experience. Do folks think things are going well? It's hard for people, I guess, to evaluate that externally, but we say a lot, that's our guiding principle.

If we're doing good by our customers, if we're being good long-term partners and we're listening to what their real needs are, what they actually are focused on and can deliver, then that's going to lead to incredible growth. It's going to lead to an increase in the number of lives that we can all help save together, and we're going to build a lot of value for our shareholders if we follow those principles.

Patrick Wood
Head of US MedTech Research, UBS

If you were to look forward 10 years, what would be your absolute dream of success looking like for Strata? What would be your dream of like, this is exactly what we hoped would happen? What would the company look like 10 years from now?

Will Heyburn
Co-CEO and CFO, Strata

Hopefully, 10 years from now, there's not a transplant waiting list. Hopefully, the people that aren't allowed to be on the transplant waiting list today, the millions of people that are suffering, are able to get organs that can improve their life or can save their life when maybe the algorithms don't think today that that's a good allocation of an organ. We're doing that by having made the whole supply base more efficient. We could be benefiting from xenotransplant organs as a bridge to allow us enough time to get a long-term solution. I hope also that we're a more diversified company. All the little things we've talked about that we're building and beachheads that we've built have become real large growing businesses with acquisition strategies that are enhancing that growth in their own right.

I think that that's hopefully, with the work that we're doing and the work that all of our partners are doing, a place that's a very realistic future for us.

Patrick Wood
Head of US MedTech Research, UBS

It's an amazing vision. I've managed to get through almost all the time without going insane depth organ by organ, but I have to ask just one, just out of curiosity. How's your mix looking today of typically by organ? Do you envisage a future where that's going to look different for any reason? I know DCD and DBD, there's a lot of dynamics there, but where do you see the greatest opportunity from an organ perspective?

Will Heyburn
Co-CEO and CFO, Strata

Our logistics mix very much matches the industry, but being focused on heart, liver, lung, because that's the time-critical movement that we do hand carry for kidneys. In the clinical side of our business, we're probably a little more focused on heart and lung for the surgical recovery piece, just because of the complexity of that. Our NRP, abdominal and cardiothoracic, but probably a little more on the abdominal side today. We're seeing more and more OPOs start to think about or start to begin offering cardioabdominal.

Patrick Wood
Head of US MedTech Research, UBS

Awesome. Well, Matt, thank you so much. Really appreciate it.

Matt Schneider
CFO of Clinical Services and VP of Finance and Investor Relations, Strata

Thank you.